ArticleInfection & chemotherapy2026
Long-Term Effectiveness and Tolerability of Dolutegravir/Lamivudine in Korea: A 3-Year Follow Up Study.
Article in Infection & chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cutting-edge developments in computer-aided anti-HIV drug design.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSeveral studies have demonstrated the real-world efficacy and tolerability of dolutegravir/lamivudine (DTG/3TC). However, data from Asian countries-particularly regarding long-term use-remain limited. MATERIALS AND
methodsWe conducted a retrospective cohort study of adult people living with human immunodeficiency viruses (PLWH) who were treated with DTG/3TC at a tertiary hospital in Korea. Individuals with a 36-month observation period from the initiation of DTG/3TC were included in the study, as well as those who switched to other regimens during follow-up were also analysed. Both treatment-naive individuals and those who switched to DTG/3TC from other regimens were included. Baseline characteristics, DTG/3TC maintenance rates, effectiveness, and changes in metabolic parameters over 36 months were evaluated.
resultsBetween July 2020 and April 2024, 305 PLWH received DTG/3TC, of whom 134 had an observation period of 36 months or longer. Most PLWH were male (94.0%), with a median age was 45.5 years. No participant switched from DTG/3TC to other regimens during the 36-month follow-up period. In the treatment-naïve group, HIV RNA levels remained <50 copies/mL from 6 to 36 months after starting DTG/3TC treatment. In the switching group, 99.2% maintained <50 copies/mL at 36 months. Among the treatment-naïve individuals, the CD4+ T cell count increased from a median of 494 cells/μL at baseline to 795 cells/μL at 36 months. During the 36-month follow-up, no significant changes were observed in lipid profiles or body weights in either the treatment-naïve or switching groups, apart from an increase in high-density lipoprotein cholesterol in the switching group.
conclusionDTG/3TC demonstrated sustained viral suppression and maintained CD4 count, with no significant adverse effects on lipid profiles or body weight.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.